Market research
ANEB Anebulo Pharmaceuticals Inc
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
Market facts
- Market cap
- 14M
- P/E ratio
- Not available
- Analyst target
- 3
- Dividend yield
- Not available
- Beta
- -1.83
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US0345691036
- Market cap
- 14M
- P/E ratio
- Not available
- Analyst target
- 3
- Dividend yield
- Not available
- Beta
- -1.83
About
About Anebulo Pharmaceuticals Inc
Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing treatments for unintentional cannabis poisoning, acute cannabinoid intoxication, and acute cannabis-induced conditions in the United States. The company's lead product candidate is the selonabant, a small-molecule antagonist of cannabinoid binding receptor type-1(CB1), which is in a phase II clinical trial to address the unmet medical need for a specific antidote for cannabis toxicity. Anebulo Pharmaceuticals, Inc. was incorporated in 2020 and is headquartered in Lakeway, Texas.
Visit company websiteCommunity
Investor discussion
0 comments
Sign in to join the ANEB discussion.
No comments yet
Start a focused discussion about ANEB.